Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies
An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.
Source: news-medical.net